Compare IDEXX Laboratories, Inc. (IDXX) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Invesco Preferred ETF — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Invesco Preferred ETF trades at $10.01 (market cap $3.60B). The key difference: IDEXX Laboratories, Inc. is far larger — about 11.2× Invesco Preferred ETF's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 5,986,026). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Invesco Preferred ETF for 95 Days on average.
| IDXX | PGX | |
|---|---|---|
Market Cap | $40.43B | $3.60B |
Volume | 692,164 | 5,986,026 |
Sector | Health | — |
52-Week High | $766.68 | $11.61 |
52-Week Low | $504.70 | $9.97 |
Typical Hold Time | 46 Days | 95 Days |
Enterprise Value | $41.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
PGX trades at $10.03 with a modest 0.6% daily gain, though technical indicators show a bearish trend with moving averages and ADX signaling selling pressure. The stock faces fundamental data gaps with key valuation and profitability metrics unavailable. Recent corporate actions include scheduled dividend payments of $0.06 per share in July and September 2026, providing income potential for shareholders.
The outlook remains cautious due to incomplete financial data and bearish technical signals. Investment opportunity exists through dividend income, but risks include limited fundamental visibility and technical weakness. Investors require updated SEC filings and analyst coverage to assess true valuation and growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
